Effer-K 20 mEq Unflavored
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Effer-K 20 mEq Unflavored
- Generic name
- POTASSIUM BICARBONATE
- Manufacturer
- Nomax Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 8869554b-ff0b-4f0e-8a09-61e7be3b496e
- SPL ID
- ba1639f4-e624-41da-a8d7-e97676b900d7
- Version
- 4
- Effective date
- 2019-12-18
- Source export date
- 2026-09-28
- Source partition
- 2
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/f7d2b6e3f8600cd856280ab55a9c6fa54a642647191d164f9d1110e89f3f4097/drug-label-0002-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:15:53
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Effer-K 10 mEq Unflavored | openfda.brand_name | |
| brand name | Effer-K 10 mEq Cherry Vanilla | openfda.brand_name | |
| brand name | Effer-K 20 mEq Unflavored | openfda.brand_name | |
| brand name | Effer-K 20 mEq Orange Cream | openfda.brand_name | |
| generic name | POTASSIUM BICARBONATE | openfda.generic_name | |
| manufacturer name | Nomax Inc. | openfda.manufacturer_name | |
| ndc | package | 51801-011-30 | openfda.package_ndc |
| ndc | package | 51801-012-30 | openfda.package_ndc |
| ndc | package | 51801-013-30 | openfda.package_ndc |
| ndc | package | 51801-014-30 | openfda.package_ndc |
| ndc | product | 51801-013 | openfda.product_ndc |
| ndc | product | 51801-014 | openfda.product_ndc |
| ndc | product | 51801-012 | openfda.product_ndc |
| ndc | product | 51801-011 | openfda.product_ndc |
| ndc11 | package | 51801001330 | derived:openfda.package_ndc |
| ndc11 | package | 51801001130 | derived:openfda.package_ndc |
| ndc11 | package | 51801001430 | derived:openfda.package_ndc |
| ndc11 | package | 51801001230 | derived:openfda.package_ndc |
| rxcui | 1111267 | openfda.rxcui | |
| rxcui | 1111263 | openfda.rxcui | |
| rxcui | 1111265 | openfda.rxcui | |
| rxcui | 1111261 | openfda.rxcui | |
| spl id | ba1639f4-e624-41da-a8d7-e97676b900d7 | id | |
| spl set id | 8869554b-ff0b-4f0e-8a09-61e7be3b496e | set_id | |
| unii | HM5Z15LEBN | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings In patients with hyperkalemia and impaired mechanisms for excreting potassium the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment. Note: There is no conclusive evidence that potassium supplements lower blood pressure in hypertensive patients.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
Adverse Reactions One of the most severe adverse effects is hyperkalemia (see Contraindications , Warnings and Overdosage ). The most common adverse reactions to oral potassium salts are nausea, vomiting, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals, or reducing the dose. Skin rash has been reported rarely.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.